News & Updates

Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.

People living with HIV (PWH) may soon benefit from a once-weekly treatment regimen instead of the standard daily antiretroviral therapy to manage their condition. Two recent phase III trials, ISLEND-1 and -2, have shown the efficacy of islatravir/lenacapavir (ISL/LEN) vs bictegravir/emtricitabine/tenofovir/alafenamide (B/F/TAF) or standard of care (SOC).